Efficacy of methotrexate/vinblastine/doxorubicin/cisplatin combination in gemcitabine-pretreated patients with advanced urothelial cancer: a retrospective analysis

References

• Bamias A, Tiliakos I, Karali MD, Dimopoulos MA. Systemic chemotherapy in inoperable or metastatic bladder cancer. Ann Oncol. 2006;17:553–561.
   PubMed Web of Science ®Google Scholar
• von der Maase H, Hansen SW, Roberts JT, et al. Gemcitabine and cisplatin versus methotrexate, vinblastine, doxorubicin, and cisplatin in advanced or metastatic bladder cancer: results of a large randomized, multinational, multicenter, phase III study. J Clin Oncol. 2000;18:3068–3077.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Deliveliotis C, Moulopoulos LA, et al. Treatment of patients with metastatic urothelial carcinoma and impaired renal function with single-agent docetaxel. Urology. 1998;52:56–60.
   PubMed Web of Science ®Google Scholar
• Shannon C, Crombie C, Brooks A, Lau H, Drummond M, Gurney H. Carboplatin and gemcitabine in metastatic transitional cell carcinoma of the urothelium: effective treatment of patients with poor prognostic features. Ann Oncol. 2001;12:947–952.
   PubMed Web of Science ®Google Scholar
• Linardou H, Aravantinos G, Efstathiou E, et al. Gemcitabine and carboplatin combination as first-line treatment in elderly patients and those unfit for cisplatin-based chemotherapy with advanced bladder carcinoma: Phase II study of the Hellenic Co-operative Oncology Group. Urology. 2004;64:479–484.
   PubMed Web of Science ®Google Scholar
• Bamias A, Moulopoulos LA, Koutras A, et al. The combination of gemcitabine and carboplatin as first-line treatment in patients with advanced urothelial carcinoma. A Phase II study of the Hellenic Cooperative Oncology Group. Cancer. 2006;106:297–303.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, Calabro F, Pizzocaro G, Marini L, Schnetzer S, Sella A. Chemotherapy with an every-2-week regimen of gemcitabine and paclitaxel in patients with transitional cell carcinoma who have received prior cisplatin-based therapy. Cancer. 2001;92:2993–2998.
   PubMed Web of Science ®Google Scholar
• Meluch AA, Greco FA, Burris HA 3rd, et al. Paclitaxel and gemcitabine chemotherapy for advanced transitional-cell carcinoma of the urothelial tract: a phase II trial of the Minnie Pearl Cancer Research Network. J Clin Oncol. 2001;19:3018–3024.
   PubMed Web of Science ®Google Scholar
• Kanai K, Kikuchi E, Ohigashi T, et al. Gemcitabine and paclitaxel chemotherapy for advanced urohtelial carcinoma in patients who received prior cisplatin-based chemotherapy. Int J Clin Oncol. 2008;13:510–514.
   PubMed Web of Science ®Google Scholar
• Takahashi T, Higashi S, Nishiyama H, et al. Biweekly paclitaxel and gemcitabine for patients with advanced urothelial cancer ineligible for cisplatin-based regimen. Jpn J Clin Oncol. 2006;36:104–108.
   PubMed Web of Science ®Google Scholar
• Suyama T, Ueda T, Fukasawa S, et al. Combination of gemcitabine and paclitaxel as second-line chemotherapy for advanced urothelial carcinoma. Jpn J Clin Oncol. 2009;39:244–250.
   PubMed Web of Science ®Google Scholar
• Sweeney CJ, Roth BJ, Kabbinavar FF, et al. Phase II study of pemetrexed for second-line treatment of transitional cell cancer of the urothelium. J Clin Oncol. 2006;24:3451–3457.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Von der Maase H, Theodore C, et al. Randomised phase III trial of vinflunine (V) plus best supportive care (B) vs B alone as 2nd line therapy after a platinum-containing regimen in advanced transitional cell carcinoma of the urothelium (TCCU). J Clin Oncol. 2008;26 Suppl 15:5028.
   Google Scholar
• Tu SM, Hossan E, Amato R, Kilburn R, Logothetis CJ. Paclitaxel, cisplatin and methotrexate combination chemotherapy is active in refractory urothelial malignancies. J Urol. 1995;154:1719–1722.
   PubMed Web of Science ®Google Scholar
• de Mulder PH, Theodore C, Sella A, et al. Phase II EORTC trial with 5-fluorouracil, cisplatin and interferon-aloha as second-line treatment of advanced transitional cell cancer of the urothelial tract. Ann Oncol. 2000;11:1391–1394.
   PubMed Web of Science ®Google Scholar
• Pagliaro LC, Millikan RE, Tu SM, et al. Cisplatin, gemcitabine, and ifosfamide as weekly therapy: a feasibility and phase II study of salvage treatment for advanced transitional-cell carcinoma. J Clin Oncol. 2002;20:2965–2970.
   PubMed Web of Science ®Google Scholar
• Han KS, Joung JY, Kim TS, et al. Methotrexate, vinblastine, doxorubicin and cisplatin combination regimen as salvage chemotherapy for patients with advanced or metastatic transitional cell carcinoma after failure of gemcitabine and cisplatin chemotherapy. Br J Cancer. 2008;98:86–90.
   PubMed Web of Science ®Google Scholar
• Uhm JE, Lim HY, Kim WS, et al. Paclitaxel with cisplatin as salvage treatment for patients with previously treated advanced transitional cell carcinoma of the urothelial tract. Neoplasia. 2007;9:18–22.
   Web of Science ®Google Scholar
• Pectasides D, Aravantinos G, Kalofonos H, et al. Combination chemotherapy with gemcitabine and ifosfamide as second-line treatment in metastatic urothelial cancer. A phase II trial conducted by the Hellenic Cooperative Oncology Group. Ann Oncol. 2001;12:1417–1422.
   PubMed Web of Science ®Google Scholar
• Paz-Ares L, Bezares S, Tabernero JM, Tabernero JM, Castellanos D, Cortes-Funes H. Review of a promising new agent – pemetrexed disodium. Cancer. 2003;97 Suppl 8:2056–2063.
   Google Scholar
• Vaughn DJ, Srinivas S, Stadler WM, et al. Phase II study of single-agent vinflunine in platinum-refractory transitional cell carcinoma of the urothelium (TCCU) [Abstract 15543]. J Clin Oncol. 2007;18S:391.
   Google Scholar
• Lassiter LK, Tummala MK, Hussain MH, Stadler WM, Petrylak DP, Carducci MA. Phase II open-label study of oral piritrexim in patients with advanced carcinoma of the urothelium who have experienced failure with standard chemotherapy. Clin Genitourin Cancer. 2008;6:31–35.
   PubMed Web of Science ®Google Scholar
• Bellmunt J, Albiol S, Suarez C, Albanell J. Optimizing therapeutic strategies in advanced bladder cancer: update on chemotherapy and the role of targeted agents. Crit Rev Oncol/Haematol. 2009;69:211–222.
   Google Scholar
• Bamias A, Aravantinos G, Deliveliotis C, et al. Docetaxel and cisplatin with granulocyte colony-stimulating factor (G-CSF) versus M-VAC with G-CSF in advanced urothelial carcinoma: a multicenter, randomized, phase III study conducted by the Hellenic Cooperative Oncology Group. J Clin Oncol. 2004;22:220–228.
   PubMed Web of Science ®Google Scholar
• Sternberg CN, de Mulder PHM, Schornagel JH, et al. Randomized phase III trial of high-dose-intensity methotrexate, vinblastine, doxorubicin, and cisplatin (MVAC) chemotherapy and recombinant human granulocyte colony-stimulating factor versus the classic MVAC in advanced urothelial tract tumors: European Organization for Research and Treatment of Cancer protocol no. 30924. J Clin Oncol. 2001;19:2638–2646.
   PubMed Web of Science ®Google Scholar
• Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. J Natl Cancer Inst. 2000;92(3):205–216.
   PubMed Web of Science ®Google Scholar
• Bajorin DF, Dodd PM, Mazumdar M, et al. Long-term survival in metastatic transitional-cell carcinoma and prognostic factors predicting outcome of therapy. J Clin Oncol. 1999;17:3173–3181.
   PubMed Web of Science ®Google Scholar
• Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron. 1976;16:31–41.
   PubMed Web of Science ®Google Scholar
• Stenzl A, Cowan NC, de Santis M, et al. The updated EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2009;55:815–825.
   PubMed Web of Science ®Google Scholar
• Galsky MD, Mironov S, Iasonos A, Scattergood J, Boyle MG, Bajorin DF. Phase II trial of pemetrexed as second-line therapy in patients with metastatic urothelial carcinoma. Invest New Drugs. 2007;25:265–270.
   PubMed Web of Science ®Google Scholar
• Albers P, Siener R, Härtlein M, et al. German TCC Study Group of the German Association of Urologic Oncology: Gemcitabine monotherapy as second-line treatment in cisplatin-refractory transitional cell carcinoma – prognostic factors for response and improvement of quality of life. Onkologie. 2002;25:47–52.
   PubMedGoogle Scholar
• Philips G, Halabi S, Sanford B, Bajorin D, Small E. Phase II trial of cisplatin (C), fixed-dose rate gemcitabine (G) and gefitinib for advanced transitional cell carcinoma (TCC) of the urothelial tract: Preliminary results of CALGB 90102 [Abstract 4540]. J Clin Oncol. 2004;22: 14S (391s).
   Google Scholar
• Hussain MH, MacVicar GR, Petrylak DP, et al. Trastuzumab, paclitaxel, carboplatin, and gemcitabine in advanced human epidermal growth factor receptor-2/neu-positive urothelial carcinoma: results of a multicenter phase II National Cancer Institute trial. J Clin Oncol. 2007;25:2218–2224.
   Google Scholar